1.Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases.
Alessandra Billi FALCÃO-GONÇALVES ; Denis Bernardi BICHUETTI ; Enedina Maria Lobato DE OLIVEIRA
Journal of Clinical Neurology 2018;14(3):351-358
BACKGROUND AND PURPOSE: Optic neuritis (ON) is an inflammation of the optic nerve that can be recurrent, with unilateral or bilateral presentation. Diagnosing recurrent cases may be challenging. We aimed to compare patients with recurrent ON as their initial symptom according to their following final diagnoses: multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), or chronic relapsing inflammatory optic neuropathy (CRION). METHODS: The medical records of patients with initial recurrent ON who were followed at the Neuroimmunology Clinic of the Federal University of São Paulo between 2004 and 2016 were analyzed retrospectively. Patients were classified according to their final diagnosis into MS, NMOSD, or CRION, and the characteristics of these groups were compared to identify predictive factors. RESULTS: Thirty-three patients with recurrent ON were included, and 6, 14, and 13 had final diagnoses of MS, NMOSD, and CRION, respectively. Most of the patients were female with unilateral and severe ON in their first episode, and the initial Visual Functional System Score (VFSS) was ≥5 in 63.6%, 85.7%, and 16.7% of the patients with CRION, NMOSD, and MS, respectively. Anti-aquaporin-4 antibodies were detected in 9 of 21 (42.8%) tested patients. Seven of nine (77.8%) seropositive NMOSD patients experienced transverse myelitis episodes during the follow-up period. A multivariate regression analysis showed that the VFSS at the last medical appointment predicted the final diagnosis. CONCLUSIONS: A lower VFSS at the last medical appointment was predictive of MS. Patients with NMOSD and CRION have similar clinical characteristics, whereas NMOSD patients tend to have worse visual acuity.
Antibodies
;
Aquaporin 4
;
Demyelinating Diseases*
;
Diagnosis
;
Female
;
Follow-Up Studies
;
Humans
;
Inflammation
;
Medical Records
;
Multiple Sclerosis
;
Myelitis, Transverse
;
Neuromyelitis Optica
;
Optic Nerve
;
Optic Nerve Diseases
;
Optic Neuritis*
;
Recurrence
;
Retrospective Studies
;
Visual Acuity
2.Pneumoretroperitoneum and Sepsis After Transanal Endoscopic Resection of a Rectal Lateral Spreading Tumor.
Bruno Augusto Alves MARTINS ; Marcelo de Melo Andrade COURA ; Romulo Medeiros de ALMEIDA ; Natascha Mourão MOREIRA ; João Batista de SOUSA ; Paulo Gonçalves de OLIVEIRA
Annals of Coloproctology 2017;33(3):115-118
Transanal endoscopic microsurgery is considered a safe, appropriate, and minimally invasive approach, and complications after endoscopic microsurgery are rare. We report a case of sepsis and pneumoretroperitoneum after resection of a rectal lateral spreading tumor. The patient presented with rectal mucous discharge. Colonoscopy revealed a rectal lateral spreading tumor. The patient underwent an endoscopic transanal resection of the lesion. He presented with sepsis of the abdominal focus, and imaging tests revealed pneumoretroperitoneum. A new surgical intervention was performed with a loop colostomy. Despite the existence of other reports on pneumoretroperitoneum after transanal endoscopic microsurgery, what draws attention to this case is the association with sepsis.
Colonoscopy
;
Colostomy
;
Humans
;
Microsurgery
;
Retropneumoperitoneum*
;
Sepsis*
;
Transanal Endoscopic Microsurgery
3.Relationship Between Chloroquine or Hydroxychloroquine Use and Hearing Disorders: A Systematic Review and Meta-Analysis
Maria Renata JOSÉ ; Jéssica da Silva ORTEGA ; Jordana Batista Correia BARAN ; Débora LÜDERS ; Claudia Giglio de Oliveira GONÇALVES ; Bianca Simone ZEIGELBOIM ; Karinna Veríssimo Meira TAVEIRA ; José Fernando POLANSKI ; Rosane Sampaio SANTOS ; Camila de Castro CORRÊA ; Cristiano Miranda DE ARAUJO
Journal of Audiology & Otology 2024;28(2):126-145
Background and Objectives:
Chloroquine and its analog hydroxychloroquine are derivatives of 4-aminoquinoline and are regularly used in the treatment of malaria and autoimmune diseases. Among the side effects of these drugs, alterations associated with the auditory system are frequently mentioned. Thus, the aim of this systematic review is to systematically review publications on hearing disorders and chloroquine or hydroxychloroquine use.
Materials and Methods:
Inclusion criteria were observational or interventional studies on audiological assessment in participants who were using chloroquine or hydroxychloroquine. The methodological quality was independently assessed by two reviewers using the Meta-Analysis of Statistics: assessment and review Instrument. The certainty of the evidence was assessed using the GRADE tool.
Results:
A total of 1,372 non-duplicate papers were screened, out of which 17 were included in the final qualitative synthesis, and 5 studies in the meta-analysis. The odds ratio for the two subgroups evaluated did not show significance with no heterogeneity between the effects observed between the different diseases (I2=0%) and obtaining the global estimate of 0.76 (95% confidence interval [CI]=0.41–1.39; p>0.05). Despite the inclusion of papers with different disease samples, the heterogeneity observed in the analysis was low (I2= 0%) and prediction interval (95% PI=0.32–1.80; p>0.05) remained close to that estimated by the CI (95% CI=0.41–1.39; p>0.05). The certainty of the evidence assessed by the GRADE tool was considered very low due to the risk of bias, indirect evidence, and imprecision.
Conclusions
The findings of this study suggest that the use of chloroquine/hydroxychloroquine is not associated with hearing disorders.
4.Relationship Between Chloroquine or Hydroxychloroquine Use and Hearing Disorders: A Systematic Review and Meta-Analysis
Maria Renata JOSÉ ; Jéssica da Silva ORTEGA ; Jordana Batista Correia BARAN ; Débora LÜDERS ; Claudia Giglio de Oliveira GONÇALVES ; Bianca Simone ZEIGELBOIM ; Karinna Veríssimo Meira TAVEIRA ; José Fernando POLANSKI ; Rosane Sampaio SANTOS ; Camila de Castro CORRÊA ; Cristiano Miranda DE ARAUJO
Journal of Audiology & Otology 2024;28(2):126-145
Background and Objectives:
Chloroquine and its analog hydroxychloroquine are derivatives of 4-aminoquinoline and are regularly used in the treatment of malaria and autoimmune diseases. Among the side effects of these drugs, alterations associated with the auditory system are frequently mentioned. Thus, the aim of this systematic review is to systematically review publications on hearing disorders and chloroquine or hydroxychloroquine use.
Materials and Methods:
Inclusion criteria were observational or interventional studies on audiological assessment in participants who were using chloroquine or hydroxychloroquine. The methodological quality was independently assessed by two reviewers using the Meta-Analysis of Statistics: assessment and review Instrument. The certainty of the evidence was assessed using the GRADE tool.
Results:
A total of 1,372 non-duplicate papers were screened, out of which 17 were included in the final qualitative synthesis, and 5 studies in the meta-analysis. The odds ratio for the two subgroups evaluated did not show significance with no heterogeneity between the effects observed between the different diseases (I2=0%) and obtaining the global estimate of 0.76 (95% confidence interval [CI]=0.41–1.39; p>0.05). Despite the inclusion of papers with different disease samples, the heterogeneity observed in the analysis was low (I2= 0%) and prediction interval (95% PI=0.32–1.80; p>0.05) remained close to that estimated by the CI (95% CI=0.41–1.39; p>0.05). The certainty of the evidence assessed by the GRADE tool was considered very low due to the risk of bias, indirect evidence, and imprecision.
Conclusions
The findings of this study suggest that the use of chloroquine/hydroxychloroquine is not associated with hearing disorders.
5.Relationship Between Chloroquine or Hydroxychloroquine Use and Hearing Disorders: A Systematic Review and Meta-Analysis
Maria Renata JOSÉ ; Jéssica da Silva ORTEGA ; Jordana Batista Correia BARAN ; Débora LÜDERS ; Claudia Giglio de Oliveira GONÇALVES ; Bianca Simone ZEIGELBOIM ; Karinna Veríssimo Meira TAVEIRA ; José Fernando POLANSKI ; Rosane Sampaio SANTOS ; Camila de Castro CORRÊA ; Cristiano Miranda DE ARAUJO
Journal of Audiology & Otology 2024;28(2):126-145
Background and Objectives:
Chloroquine and its analog hydroxychloroquine are derivatives of 4-aminoquinoline and are regularly used in the treatment of malaria and autoimmune diseases. Among the side effects of these drugs, alterations associated with the auditory system are frequently mentioned. Thus, the aim of this systematic review is to systematically review publications on hearing disorders and chloroquine or hydroxychloroquine use.
Materials and Methods:
Inclusion criteria were observational or interventional studies on audiological assessment in participants who were using chloroquine or hydroxychloroquine. The methodological quality was independently assessed by two reviewers using the Meta-Analysis of Statistics: assessment and review Instrument. The certainty of the evidence was assessed using the GRADE tool.
Results:
A total of 1,372 non-duplicate papers were screened, out of which 17 were included in the final qualitative synthesis, and 5 studies in the meta-analysis. The odds ratio for the two subgroups evaluated did not show significance with no heterogeneity between the effects observed between the different diseases (I2=0%) and obtaining the global estimate of 0.76 (95% confidence interval [CI]=0.41–1.39; p>0.05). Despite the inclusion of papers with different disease samples, the heterogeneity observed in the analysis was low (I2= 0%) and prediction interval (95% PI=0.32–1.80; p>0.05) remained close to that estimated by the CI (95% CI=0.41–1.39; p>0.05). The certainty of the evidence assessed by the GRADE tool was considered very low due to the risk of bias, indirect evidence, and imprecision.
Conclusions
The findings of this study suggest that the use of chloroquine/hydroxychloroquine is not associated with hearing disorders.
6.C57BL/6 and DBA/1 Mice Differ in Their Response to Supplementation with 1,25D and Paricalcitol.
Aline Parisoto MISSIO ; Thais Fernanda de Campos FRAGA-SILVA ; Larissa Lumi Watanabe ISHIKAWA ; Luiza Ayumi Nishiyama MIMURA ; Thais Graziela Donegá FRANÇA ; Larissa Ragozo Cardoso De OLIVEIRA ; Alexandrina SARTORI ; Sofia Fernanda Gonçalves ZORZELLA-PEZAVENTO
Biomedical and Environmental Sciences 2018;31(8):613-618
7.EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
Bruno Henrique Bressan DA COSTA ; Aline Paixão BECKER ; Luciano NEDER ; Paola Gyuliane GONÇALVES ; Cristiane DE OLIVEIRA ; Allan Dias POLVERINI ; Carlos Afonso CLARA ; Gustavo Ramos TEIXEIRA ; Rui Manuel REIS ; Lucas Tadeu BIDINOTTO
Journal of Pathology and Translational Medicine 2022;56(4):205-211
Background:
Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches.
Methods:
Spearman’s correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients’ samples, and was associated with clinicopathological data and overall survival.
Results:
In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase–Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041).
Conclusions
This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology.